On December 11, 2009 Summit Corporation plc announced that it had been awarded £2.2 million from the Wellcome Trust to fund the development of the Company's infectious disease programme targeting C. difficile, a bacteria that is posing a significant and growing healthcare threat.
The award was made through the Wellcome Trust's Seeding Drug Discovery Initiative and provides over two years of funding to develop Summit's programme through until the end of preclinical development.
Allistair Booth and Gary Howes of Fasken Martineau advised Summit Corporation plc in this matter.